(R)-2-Amino-2-methylpent-4-ynoic acid NEW

BJV, based on five major technology platforms, has developed a number of blockbuster APIs such as semaglutide and liraglutide. Meanwhile, it has formed a complete product layout in cosmetic medicines, anti-viral peptide drugs and vaccines, recombinant collagen raw materials to drugs and medical devices. With more than 20 years of experience of R&D and GMP production, BJV has become a powerful enterprise in cosmetic and pharmaceutical industry.